🟢 Gossamer Bio is trading 5.45% up in pre-market with no clear company-specific catalyst

Gossamer Bio is trading at $9.39, up 5.45%, with no clear company-specific catalyst identified in the October 15 search.

• The latest company announcement located was its September 23 seralutinib NDA submission.
• The Nasdaq Composite was down 1.22%, which does not explain Gossamer Bio’s move higher.
• Shares closed at $8.90 on October 14, down 8.76%, amid recent volatility.